menu
    • menu

    Company profile for Akari Therapeutics

    NEW Drugs in Dev: 5
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We develop life-transforming treatments for autoinflammatory diseases involving the complement (C5) and leukotriene (LTB4) pathways.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Akari Therapeuticsunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    75/76 Wimpole Street London W1G 9RT
    Telephone
    Telephone
    +44 (0)20.8004.0261
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.akaritx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Arab Health

    Arab Health

    Not Confirmed

    envelop Contact Supplier

    Arab Health

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Akari Pharma Joins Webull Financial Virtual Conference
    Akari Pharma Joins Webull Financial Virtual Conference

    05 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/05/3233091/0/en/Akari-Therapeutics-to-Participate-in-the-Corporate-Connect-Webinar-Series-Virtual-Conference-Hosted-by-Webull-Financial.html

    GLOBENEWSWIRE
    05 Feb 2026
    Share Share
    Akari Pharma Files Vital Patent, Reveals AKTX-102 For CEACAM5
    Akari Pharma Files Vital Patent, Reveals AKTX-102 For CEACAM5

    26 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/26/3225663/0/en/Akari-Therapeutics-Files-Key-Patent-and-Unveils-Second-ADC-Program-AKTX-102-Targeting-CEACAM5-Expressing-Solid-Tumors.html

    GLOBENEWSWIRE
    26 Jan 2026
    Share Share
    Akari Therapeutics: 2025 Progress, 2026 Outlook
    Akari Therapeutics: 2025 Progress, 2026 Outlook

    09 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/09/3216102/0/en/Akari-Therapeutics-Releases-New-CEO-Corner-Segment-Highlighting-2025-Progress-and-Path-to-Clinical-Transition-In-2026.html

    GLOBENEWSWIRE
    09 Jan 2026
    Share Share
    Akari Therapeutics To Present At The 2026 Biotech Showcase
    Akari Therapeutics To Present At The 2026 Biotech Showcase

    08 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/08/3215459/0/en/Akari-Therapeutics-to-Present-at-the-2026-Biotech-Showcase.html

    GLOBENEWSWIRE
    08 Jan 2026
    Share Share
    Akari Therapeutics Issues 2025 End Of Year Letter To Shareholders
    Akari Therapeutics Issues 2025 End Of Year Letter To Shareholders

    30 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/30/3211420/0/en/Akari-Therapeutics-Issues-2025-End-of-Year-Letter-to-Shareholders.html

    GLOBENEWSWIRE
    30 Dec 2025
    Share Share
    Akari Pharma Starts GMP Production For AKTX-101 ADC In Phase 1
    Akari Pharma Starts GMP Production For AKTX-101 ADC In Phase 1

    23 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/23/3209866/0/en/Akari-Therapeutics-Initiates-GMP-Manufacturing-of-AKTX-101-ADC-Program-to-Support-Phase-1-First-in-Human-Clinical-Trial.html

    GLOBENEWSWIRE
    23 Dec 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search